{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:40:12Z","timestamp":1761129612445,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00210-019-01647-w","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T15:22:22Z","timestamp":1557242542000},"page":"1097-1106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure"],"prefix":"10.1007","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1891-4524","authenticated-orcid":false,"given":"Sami","family":"Ullah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Matzneller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"1647_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr 19:716\u2013723. \n                    https:\/\/doi.org\/10.1109\/TAC.1974.1100705","journal-title":"IEEE Trans Automat Contr"},{"key":"1647_CR2","doi-asserted-by":"publisher","first-page":"S220","DOI":"10.1093\/cid\/cis001","volume":"54","author":"PG Ambrose","year":"2012","unstructured":"Ambrose PG, Drusano GL, Craig WA (2012) In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 54:S220\u2013S228. \n                    https:\/\/doi.org\/10.1093\/cid\/cis001","journal-title":"Clin Infect Dis"},{"key":"1647_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-008-9072-1","volume":"11","author":"J Beer","year":"2009","unstructured":"Beer J, Wagner CC, Zeitlinger M (2009) Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing. AAPS J 11:1\u201312. \n                    https:\/\/doi.org\/10.1208\/s12248-008-9072-1","journal-title":"AAPS J"},{"key":"1647_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/jac\/dkt444","volume":"69","author":"MJE Brill","year":"2014","unstructured":"Brill MJE, Houwink API, Schmidt S, van Dongen EPA, Hazebroek EJ, van Ramshorst B, Deneer VH, Mouton JW, Knibbe CAJ (2014) Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother 69:715\u2013723. \n                    https:\/\/doi.org\/10.1093\/jac\/dkt444","journal-title":"J Antimicrob Chemother"},{"key":"1647_CR5","unstructured":"EUCAST (2014) Consultation on proposed EUCAST telavancin breakpoint changes. http:\/\/www.eucast.org\/eucast_news\/news_singleview\/?tx_ttnews[tt_news]=114&cHash=edb6bd58f7a3d341fdc937a3f1679359"},{"key":"1647_CR6","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1128\/AAC.48.8.3043-3050.2004","volume":"48","author":"SS Hegde","year":"2004","unstructured":"Hegde SS, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J, Kaniga K, Pace J, Thomas R, Shaw JP, Obedencio G, Judice JK (2004) Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 48:3043\u20133050. \n                    https:\/\/doi.org\/10.1128\/AAC.48.8.3043-3050.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","volume":"49","author":"DL Higgins","year":"2005","unstructured":"Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:1127\u20131134. \n                    https:\/\/doi.org\/10.1128\/AAC.49.3.1127-1134.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR8","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1128\/AAC.00589-08","volume":"52","author":"A Kim","year":"2008","unstructured":"Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP (2008) In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 52:3941\u20133946. \n                    https:\/\/doi.org\/10.1128\/AAC.00589-08","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11095-010-0333-1","volume":"28","author":"EHJ Krekels","year":"2011","unstructured":"Krekels EHJ, van Hasselt JGC, Tibboel D, Danhof M, Knibbe CAJ (2011) Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res 28:797\u2013811. \n                    https:\/\/doi.org\/10.1007\/s11095-010-0333-1","journal-title":"Pharm Res"},{"key":"1647_CR10","doi-asserted-by":"publisher","first-page":"e00281","DOI":"10.1128\/AAC.00281-17","volume":"61","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, Andes DR (2017) Comparative pharmacodynamics of telavancin and vancomycin in the neutropenic murine thigh and lung infection models against Staphylococcus aureus. Antimicrob Agents Chemother 61:e00281\u2013e00217. \n                    https:\/\/doi.org\/10.1128\/AAC.00281-17","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR11","unstructured":"Lodise T, Patel N, Hedge S, et al (2010) Mouse thigh MRSA infection model data and mathematical modelling to determine telavancin dosing for complicated skin and skin structure infection trials. In: Eur Congr Clin Microbiol Infect Dis. Blackwell Publishing, Vienna"},{"key":"1647_CR12","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1128\/AAC.00383-11","volume":"56","author":"TP Lodise","year":"2012","unstructured":"Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere SL (2012) Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob Agents Chemother 56:2062\u20132066. \n                    https:\/\/doi.org\/10.1128\/AAC.00383-11","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR13","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1128\/AAC.01110-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Gotfried M, Barriere S, Drusano GL (2008) Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 52:2300\u20132304. \n                    https:\/\/doi.org\/10.1128\/AAC.01110-07","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR14","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1093\/jac\/dkw269","volume":"71","author":"P Matzneller","year":"2016","unstructured":"Matzneller P, \u00d6sterreicher Z, Reiter B, Lackner E, Stimpfl T, Zeitlinger M (2016) Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study. J Antimicrob Chemother 71:3179\u20133184. \n                    https:\/\/doi.org\/10.1093\/jac\/dkw269","journal-title":"J Antimicrob Chemother"},{"key":"1647_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185\u2013202. \n                    https:\/\/doi.org\/10.1007\/s10928-007-9081-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1647_CR16","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1128\/AAC.05915-11","volume":"56","author":"E Samara","year":"2012","unstructured":"Samara E, Shaw J-P, Barriere SL, Wong SL, Worboys P (2012) Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother 56:2067\u20132073. \n                    https:\/\/doi.org\/10.1128\/AAC.05915-11","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11:558\u2013569. \n                    https:\/\/doi.org\/10.1208\/s12248-009-9133-0","journal-title":"AAPS J"},{"key":"1647_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejps.2013.11.004","volume":"57","author":"A Schaeftlein","year":"2014","unstructured":"Schaeftlein A, Minichmayr IK, Kloft C (2014) Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data. Eur J Pharm Sci 57:68\u201373. \n                    https:\/\/doi.org\/10.1016\/j.ejps.2013.11.004","journal-title":"Eur J Pharm Sci"},{"key":"1647_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","volume":"49","author":"JP Shaw","year":"2005","unstructured":"Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S (2005) Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 49:195\u2013201. \n                    https:\/\/doi.org\/10.1128\/AAC.49.1.195-201.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR20","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1128\/AAC.50.2.788-790.2006","volume":"50","author":"HK Sun","year":"2006","unstructured":"Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP (2006) Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 50:788\u2013790. \n                    https:\/\/doi.org\/10.1128\/AAC.50.2.788-790.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"1647_CR21","unstructured":"Theravance (2016) VIBATIV (telavancin) prescribing information. \n                    https:\/\/www.vibativ.com\/pdf\/PrescribingInformation.pdf"},{"key":"1647_CR22","unstructured":"Theravance (2008) Telavancin for the treatment of complicated skin and skin structure infections FDA briefing document for anti-infective drugs advisory committee meeting. \n                    https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4394b2-01-FDA.pdf"},{"key":"1647_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2007.11.011","volume":"60","author":"BT Tsuji","year":"2008","unstructured":"Tsuji BT, Leonard SN, Rhomberg PR, Jones RN, Rybak MJ (2008) Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn Microbiol Infect Dis 60:441\u2013444. \n                    https:\/\/doi.org\/10.1016\/J.DIAGMICROBIO.2007.11.011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1647_CR24","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1023\/B:PHAM.0000041468.00587.c6","volume":"21","author":"K Tunblad","year":"2004","unstructured":"Tunblad K, Hammarlund-Udenaes M, Jonsson EN (2004) An integrated model for the analysis of pharmacokinetic data from microdialysis experiments. Pharm Res 21:1698\u20131707. \n                    https:\/\/doi.org\/10.1023\/B:PHAM.0000041468.00587.c6","journal-title":"Pharm Res"},{"key":"1647_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jac\/12.2.105","volume":"12","author":"R Wise","year":"1983","unstructured":"Wise R (1983) Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. II. Studies in man. J Antimicrob Chemother 12:105\u2013118","journal-title":"J Antimicrob Chemother"},{"key":"1647_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/jac\/dkn273","volume":"62","author":"SL Wong","year":"2008","unstructured":"Wong SL, Barriere SL, Kitt MM, Goldberg MR (2008) Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 62:780\u2013783. \n                    https:\/\/doi.org\/10.1093\/jac\/dkn273","journal-title":"J Antimicrob Chemother"},{"key":"1647_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00228-015-1847-6","volume":"71","author":"PD Worboys","year":"2015","unstructured":"Worboys PD, Wong SL, Barriere SL (2015) Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol 71:707\u2013714. \n                    https:\/\/doi.org\/10.1007\/s00228-015-1847-6","journal-title":"Eur J Clin Pharmacol"},{"key":"1647_CR28","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/bcp.13306","volume":"83","author":"DFB Wright","year":"2017","unstructured":"Wright DFB, Duffull SB (2017) A general empirical model for renal drug handling in pharmacokinetic analyses. Br J Clin Pharmacol 83:1869\u20131872. \n                    https:\/\/doi.org\/10.1111\/bcp.13306","journal-title":"Br J Clin Pharmacol"},{"key":"1647_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1124\/dmd.105.008326","volume":"34","author":"A Zandvliet","year":"2006","unstructured":"Zandvliet A, Copalu W, Schellens JHM et al (2006) Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metab Dispos 34:1041\u20131046. \n                    https:\/\/doi.org\/10.1124\/dmd.105.008326","journal-title":"Drug Metab Dispos"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01647-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-019-01647-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01647-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T23:07:55Z","timestamp":1588633675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-019-01647-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1007\/s00210-019-01647-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"type":"print","value":"0028-1298"},{"type":"electronic","value":"1432-1912"}],"subject":[],"published":{"date-parts":[[2019,5,6]]},"assertion":[{"value":"12 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}